Faeth Therapeutics, Inc. Operating Expenses
Faeth Therapeutics, Inc. (FTH) reported Operating Expenses of $18.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- Faeth Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $18.39M, a 253.15% increase year-over-year.
- Faeth Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $170.63M, a 2245.71% increase year-over-year.
- Faeth Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $4.96M, a 40.09% decline year-over-year.
- Faeth Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $4.85M, a 37.99% decline year-over-year.
- Faeth Therapeutics, Inc. operating expenses for fiscal 2025 was $22.29M, a 31.66% decline from fiscal 2024.
- Faeth Therapeutics, Inc. operating expenses for fiscal 2024 was $32.61M, a 12.01% decline from fiscal 2023.
- Faeth Therapeutics, Inc. operating expenses for fiscal 2023 was $37.06M, a 26.15% decline from fiscal 2022.
- Faeth Therapeutics, Inc. operating expenses for fiscal 2022 was $50.19M, a 33.90% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.39M 10-Q · filed 2026-08-04 | $189.01M 10-Q · filed 2026-08-04 | $193.97M derived: sum of 3 quarters · filed 2026-08-04 | $198.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $170.63M 10-Q · filed 2026-05-15 | $175.58M derived: sum of 2 quarters · filed 2026-05-15 | $180.44M derived: sum of 3 quarters · filed 2026-05-15 | $185.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $9.81M derived: sum of 2 quarters · filed 2026-03-30 | $15.01M derived: sum of 3 quarters · filed 2026-08-04 | $22.29M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.85M 10-Q · filed 2025-11-14 | $10.06M derived: sum of 2 quarters · filed 2026-08-04 | $17.33M 10-Q · filed 2025-11-14 | $25.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.21M 10-Q · filed 2026-08-04 | $12.48M 10-Q · filed 2026-08-04 | $20.75M derived: sum of 3 quarters · filed 2026-08-04 | $28.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $7.27M 10-Q · filed 2026-05-15 | $15.55M derived: sum of 2 quarters · filed 2026-05-15 | $23.37M derived: sum of 3 quarters · filed 2026-05-15 | $31.16M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $16.10M derived: sum of 2 quarters · filed 2026-03-30 | $23.88M derived: sum of 3 quarters · filed 2026-03-30 | $32.61M 10-K · filed 2026-03-30 |
| 2024-09-30 | $7.82M 10-Q · filed 2025-11-14 | $15.61M derived: sum of 2 quarters · filed 2025-11-14 | $24.34M 10-Q · filed 2025-11-14 | $32.48M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $7.79M 10-Q · filed 2025-08-05 | $16.52M 10-Q · filed 2025-08-05 | $24.66M derived: sum of 3 quarters · filed 2025-08-05 | $32.40M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $8.73M 10-Q · filed 2025-05-06 | $16.87M derived: sum of 2 quarters · filed 2025-05-06 | $24.61M derived: sum of 3 quarters · filed 2025-05-06 | $34.79M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $15.88M derived: sum of 2 quarters · filed 2025-03-28 | $26.06M derived: sum of 3 quarters · filed 2025-03-28 | $37.06M 10-K · filed 2025-03-28 |
| 2023-09-30 | $7.74M 10-Q · filed 2024-11-14 | $17.91M derived: sum of 2 quarters · filed 2024-11-14 | $28.92M 10-Q · filed 2024-11-14 | $41.97M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $10.18M 10-Q · filed 2024-08-06 | $21.18M 10-Q · filed 2024-08-06 | $34.23M derived: sum of 3 quarters · filed 2024-08-06 | $48.17M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $11.01M 10-Q · filed 2024-05-09 | $24.06M derived: sum of 2 quarters · filed 2024-05-09 | $38.00M derived: sum of 3 quarters · filed 2024-05-09 | $48.71M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $13.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $26.99M derived: sum of 2 quarters · filed 2024-02-29 | $37.70M derived: sum of 3 quarters · filed 2024-02-29 | $50.19M 10-K · filed 2024-02-29 |
| 2022-09-30 | $13.94M 10-Q · filed 2023-11-07 | $24.65M derived: sum of 2 quarters · filed 2023-11-07 | $37.14M 10-Q · filed 2023-11-07 | $46.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $10.71M 10-Q · filed 2023-08-03 | $23.20M 10-Q · filed 2023-08-03 | $32.61M derived: sum of 3 quarters · filed 2023-08-03 | $42.93M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $12.49M 10-Q · filed 2023-05-09 | $21.90M derived: sum of 2 quarters · filed 2023-05-09 | $32.22M derived: sum of 3 quarters · filed 2023-05-09 | $42.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $19.73M derived: sum of 2 quarters · filed 2023-03-29 | $29.51M derived: sum of 3 quarters · filed 2023-03-29 | $37.48M 10-K · filed 2023-03-29 |
| 2021-09-30 | $10.32M 10-Q · filed 2022-11-08 | $20.10M derived: sum of 2 quarters · filed 2022-11-08 | $28.07M 10-Q · filed 2022-11-08 | $33.15M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $9.78M 10-Q · filed 2022-08-09 | $17.75M 10-Q · filed 2022-08-09 | $22.83M derived: sum of 3 quarters · filed 2022-08-09 | $28.19M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $7.97M 10-Q · filed 2022-05-10 | $13.05M derived: sum of 2 quarters · filed 2022-05-10 | $18.41M derived: sum of 3 quarters · filed 2022-05-10 | $23.32M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $10.44M derived: sum of 2 quarters · filed 2022-03-15 | $15.35M derived: sum of 3 quarters · filed 2022-03-15 | $19.45M 10-K · filed 2022-03-15 |
| 2020-09-30 | $5.36M 10-Q · filed 2021-11-10 | $10.27M derived: sum of 2 quarters · filed 2021-11-10 | $14.37M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $4.91M 10-Q · filed 2021-08-11 | $9.01M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $4.10M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |